The MDM2 proto-oncogene is overexpressed in human tumours and regulates the activities of the tumour suppressors p53 and pRB. We created mice that overexpress MDM2 under the control of the CMV promoter. These mice did not display an increased tumour incidence, but rather a speci®c skin phenotype, characterized by desquamation and hyperkeratosis. Transgenic MDM2 was found to be overexpressed in the epidermis, a tissue that normally expresses high levels of MDM2. The phenotype appeared during the ®rst week after birth and then lessened with age, closely following the level of expression of the transgene. MDM2 overexpression was associated with an increase in proliferation in the basal layer, thickening of the epidermis, altered expression of the dierentiation markers cytokeratin CK14, CK10 and CK1, and a decrease in the size and the number of granules that contain products of dierentiation. Transgenic mice on a p53 null background displayed similar although not identical changes, showing that the eects of MDM2 are to a certain degree p53 independent. The skin is a major site of MDM2 expression in mice, raising the possibility that MDM2 overexpression perturbs the normal pattern of MDM2 expression and inhibits dierentiation of the epidermis.
The MDM2 proto-oncogene is overexpressed in human tumours and regulates the activities of the tumour suppressors p53 and pRB. We created mice that overexpress MDM2 under the control of the CMV promoter. These mice did not display an increased tumour incidence, but rather a speci®c skin phenotype, characterized by desquamation and hyperkeratosis. Transgenic MDM2 was found to be overexpressed in the epidermis, a tissue that normally expresses high levels of MDM2. The phenotype appeared during the ®rst week after birth and then lessened with age, closely following the level of expression of the transgene. MDM2 overexpression was associated with an increase in proliferation in the basal layer, thickening of the epidermis, altered expression of the dierentiation markers cytokeratin CK14, CK10 and CK1, and a decrease in the size and the number of granules that contain products of dierentiation. Transgenic mice on a p53 null background displayed similar although not identical changes, showing that the eects of MDM2 are to a certain degree p53 independent. The skin is a major site of MDM2 expression in mice, raising the possibility that MDM2 overexpression perturbs the normal pattern of MDM2 expression and inhibits dierentiation of the epidermis.
Keywords: cytokeratins; desquamation; dierentiation; epidermis; proliferation/ichthyosis vulgaris Introduction p53 is mutated in more than 50% of human tumours and is a key element in the protection against tumour development (reviews: Hall and Lane, 1997; Neil et al., 1997; Morgan and Kastan, 1997; Hollstein et al., 1997; Hansen and Oren, 1997; Levine, 1997; Wang and Harris, 1997; Almog and Rotter, 1997) . However, p53 can be inactivated in tumours by other mechanisms, such as MDM2 overexpression (reviews: Piette et al., 1997; Momand and Zambetti, 1997; Haines, 1997) . p53 normally regulates its own inactivation, by inducting MDM2 expression. Down-regulation of p53 by MDM2 is critically important during embryonic development, since the lethality resulting from the inactivation of the MDM2 gene in mice is reversed by inactivation of the p53 gene (Montes de Oca Luna et al., 1995; Jones et al., 1995) . MDM2 forms a complex with p53, inhibits its ability to stimulate transcription (Thut et al., 1997) and stimulates its degradation by the ubiquitin pathway (Bottger et al., 1997; Lane and Hall, 1997; Midgley and Lane, 1997; Haupt et al., 1997; Kubbutat et al., 1997) . However, MDM2 has p53 independent activities in cell cycle progression, dierentiation and transformation.
MDM2 interacts physically and functionally with cell cycle regulators [pRb (Xiao et al., 1995) , E2F1/ DP1 (Martin et al., 1995) , CCG1/TAF II 250, the cyclin A promoter (Leveillard and Wasylyk, 1997) and p107 (Dubs-Poterszman et al., 1995) ]. MDM2 overexpression in the mammary gland leads to uncontrolled entry into S phase and polyploidy (Lundgren et al., 1997) . MDM2 inhibits muscle cell dierentiation and Myo-D dependent transactivation (Fiddler et al., 1996) . MDM2 transforms cells in culture (Cahilly-Snyder et al., 1987; Fakharzadeh et al., 1991) , by p53 dependent (Finlay, 1993; Kondo et al., 1996) and independent (Dubs-Poterszman et al., 1995) mechanisms. Both properties may be important in human tumours. Simultaneous mutation of p53 and overexpression of MDM2 is relatively rare (Florenes et al., 1994) , but results in a worst prognosis (Cordon-Cardo et al., 1994; Marks et al., 1996) . Moreover some carcinomas express MDM2 proteins that cannot interact with p53 but can transform cells in culture (Sigalas et al., 1996) . MDM2 overexpression is associated with many types of human tumours (reviews: Piette et al., 1997; Momand and Zambetti, 1997; Haines, 1997) , suggesting that MDM2 can transform dierent cell types. However, MDM2 overexpression under the control of a ubiquitous promoter in transgenic mice, did not signi®cantly increase tumour incidence, but rather aected epidermal dierentiation.
The epidermis is a continuously renewing structure that provides the organism with a protective barrier (review: Eckert et al., 1997) . Keratinocytes follow a complex developmental program as they progress from the basal to the corni®ed layer. The ®rst basal layer contains dividing cells, the second spinous layer contains extensive desmosomal connections and the third granular layer has granules composed of products of keratinocyte dierentiation such as loricrin, filaggrin, cystatin-a and lipids that are used to assemble the corneocyte membrane. In the following transition layer organelles and nucleic acids are destroyed and the ®nal keratin intermediate ®lament network and the corni®ed envelope are assembled. This speci®c type of programmed cell death has been distinguished from apoptosis, which is rather associated with pathological situations (Raskin, 1997) . The ®nal corni®ed layer contains corneocytes with a stabilized array of keratin ®laments within a covalently cross-linked protein envelope that form a continuous impermeable protective surface. Keratinocytes at dierent stages of the dierentiation program express speci®c gene products, including cytokeratins CK5 and CK14 in the basal layer, followed by CK1, CK10, involucrin, loricrin and ®laggrin in the granular layer (Byrne, 1997) . MDM2 is expressed throughout the dierent layers of the human epidermis in a p53 independent manner (Dazard et al., 1997) and its transcription is upregulated when keratinocytes are induced to dierentiate in vitro (Weinberg et al., 1995) .
We have generated transgenic mice that express MDM2 under the control of the CMV promoter. They present a speci®c phenotype, scaling of the skin associated with peeling of the corni®ed layer, a decrease in the number and the size of the granules, delayed expression of dierentiation markers and hyperkeratosis. The phenotype appears during the ®rst week of life and is closely associated with overexpression of MDM2 in the granular layer of the epidermis.
Results

Generation of MDM2 transgenic mice
Transgenic mice were generated with an expression cassette containing the human cytomegalovirus (HCMV) promoter, the 5' leader sequence from bglobin and the mouse mdm2 cDNA (Figure 1) . The cassette expresses the major 90 000 mol. wt. form of MDM2 with an amino acid substitution in the second position, a glycine in the place of cysteine, in an unstructured part of the 3D structure (Kussie et al., 1996) . This alteration does not aect the ability of MDM2 to interact with and inhibit p53 or activate E2F dependent reporters (Dubs-Poterszman et al., 1995; Leveillard and Wasylyk, 1997) . Five independent lines were established and screened for the expression of MDM2 in various tissues, at the RNA level by RT ± PCR and Northern blotting, and at the protein level by Western blotting and immunohistochemistry. The ®ve lines express dierent levels of RNA and protein, with the highest levels in H21 and H25, less in H5 and low levels in H20 and H19 (see below and data not shown). MDM2 expressing Figure 1 Schematic drawing of the HCMV-mdm2 hybrid transcription unit. The transgene contains the human CMV promoter, rabbit b globin intron II, the rabbit b-globin leader sequence, mdm2 cDNA sequences coding for the`full length' 90 K protein and the SV40 poly(A) + signal. Oligonucleotides NX30, SC205, SC209, QW238, QW236 and TY70 were used to screen for the presence of the transgene and for the analysis of RNA expression by reverse transcription and PCR Figure 2 Skin phenotype of HCMV-mdm2 transgenic mice. Four day old wild type (WT) and H25 transgenics on both p53+/+ and 7/7 backgrounds. The skin of the transgenics is peeling o and has a scaly appearance animals on a p537/7 background were generated by crossing the H25 and H21 lines with p537/7 mice (Jacks et al., 1994) .
Transgenic mice have a skin abnormality
The transgenic mice displayed a severe skin phenotype compared to the wild type animals. The skin over the whole body had a¯aky appearance with extensive desquamation, resembling ®sh scales (Figure 2 ). The phenotype was particularly striking in lines H25 (Figure 2 ) and H21, less prominent in line H5 followed by H20, and not detectable in H19 (not illustrated). The phenotype appeared two days after birth, increased in severity up to days 4 ± 5, and then decreased over the next 5 ± 10 days (Table 1) . A similar age dependence was observed with the four lines that displayed the phenotype (H21, H25, H5 and H20, Table 1 ). The more severely aected animals retained traces of the phenotype on the exposed areas of the skin (tail, ears and legs) up to one month of age (not shown). The contribution of p53 to the skin phenotype was examined with p537/7 mice. H21 and H25 p537/7 animals displayed the same abnormalities as the corresponding transgenic p53+/+ mice, with similar severity and dependence on age ( Figure 2 and Table 1 ), showing that the MDM2 generated phenotype is independent of p53.
The skin phenotype re¯ects the pattern of expression of transgenic MDM2
We examined protein expression by Western blotting using antibodies against MDM2 (Pab 365). TBP, a general transcription factor served as an internal control for loading. We found that the level of MDM2 expression re¯ects the severity of the phenotype in dierent comparisons, between lines, between animals of dierent age and between individuals from the same line. MDM2 was expressed at the highest levels in H21 and H25, at a lower level in H5, followed by H20 and H19 (Figure 3a and see Day 4 in Table 1 for the severity of the phenotype). MDM2 was detected in H20, H19 and wild type animals on the original autoradiogram (data not shown). The levels of MDM2 were highest between days 1 and 4 and decreased sharply by day 10 in lines H25 (Figure 3b ) and H21 (data not shown), following the variation of the phenotype (see Table 1 ). The severity of the phenotype varied to some extent between individuals from the same line and appeared to be correlated with the level of expression of MDM2 (data not shown). However, lines H21 and H25 in general had the most severe phenotype. Similar results were obtained by immunohistochemistry (data not shown).
The CMV promoter is active in other tissues beside the skin, suggesting that there could be other defects in the mice. The mice were studied by dissection and by sectioning both organs and whole new born animals and microscopic examination. No defects were detected, especially in the major organs where the CMV promoter might be expected to drive expression of MDM2, including thymus, spleen, lung, heart, kidney, liver, brain, stomach, skeletal muscle and the digestive tube (data not shown). The expression of MDM2 protein in dierent tissues was examined by Western blotting. In non-transgenic animals at four days of age MDM2 was detected in the skin and thymus ( Figure 3c ) and to a lesser extent in lung, heart, brain and spleen (visible on the original autoradiogram). In transgenic animals MDM2 was found to be expressed predominantly in the skin (H21, Figure 3d ; H25, Figure 3e ), although there were small increases in other tissues, including thymus, lung, heart and kidney for both H21 and H25, brain for H21 and liver for H25. Further studies by immuno-histochemical analysis of whole new-born animals and dierent tissues from four day old animal con®rmed and extended these results, showing that the major site of MDM2 expression in transgenic animals was the skin (data not illustrated). These results show that the location and severity of the phenotype correlate with the level of expression of the transgene. The lack of other detectable phenotypic changes may be due to the relatively low levels of expression of the protein or may point to a particular role of MDM2 in the skin.
The epidermis of transgenic animals is thicker and has altered granular and corni®ed layers
Semi-thin skin sections of the skin were stained and examined by light microscopy. The epidermis of 4 day old H25 transgenic mice was on average about twice as thick from the basal layer to the transition layer compared to wild type animals from the same litter ( Figure 4a , bl and tl; see also Figures 6 ± 9). Thickening was systematically observed in at least thirty animals, with skin from dierent places, including the back, the head, the tail and the abdomen. Within the epidermis, the granular layer was noticeably dierent, consisting of more cell layers with granules but with less granules per cell than normal skin ( Figure  4a , see arrows) (Holbrook, 1989) . There was no evidence of enlarged cells with giant nuclei or multinucleated cells (Lundgren et al., 1997) . Transmission electron microscopy of the granular layer con®rmed that the cells contained less granules with a smaller size (see arrows in Figure 4b ), whereas other structures, such as mitochondria (m) and desmosomes (d), appeared to be normal. The corni®ed layer of transgenic mice (Figure 4a , cl) contained an excess of incompletely dierentiated corneocytes, took up more stain, possibly due to a defective barrier function, and frequently peeled o from the rest of the epidermis. Scanning electron microscopy of the surface of the skin showed that the corni®ed layer was lost (see arrowheads, Figure 4c ), that there was less hair and that the hairs were smaller in size (see arrows and data not shown). We examined whether the histopathology was dependent upon p53. Transgenic p537/7 mice displayed the same skin phenotype as the p53+/+ mice, including thickening, loss of granules and abnormal corni®cation (H25, Figure 4d and H21, data not shown). These results show that MDM2 over-expression alters the structure of the epidermis in a p53 independent manner.
Transgenic MDM2 is expressed in the granular layer
The site of MDM2 expression in the skin of 4 day old animals was examined by immuno-histochemistry using rabbit polyclonal antibodies against MDM2 (PAb 365). In H25 transgenic mice MDM2 was detected in the nuclei of cells located mainly in the altered granular layer and also occasionally in the spinous layer ( Figure  5a ). MDM2 was also detected in invaginations of the epithelium that surround the hair. The endogenous protein in wild type animals was not detected with this technique, which is less sensitive than Western blotting. p537/7 transgenic animals, that have the same phenotypic changes as their p53+/+ counterparts, also expressed MDM2 predominantly in the expanded granular layer (Figure 5b ). Similar results were obtained in H21 mice on both backgrounds (data not shown). These results show that MDM2 is predominantly expressed in the granular layer, the layer that is visibly altered in the transgenic animals.
MDM2 expression in transgenic mice increases DNA synthesis in the skin
The increased thickness of transgenic skin suggests that MDM2 induces proliferation. DNA synthesis was detected by injecting BrdU into 4 day old animals and after 2 h skin sections were analysed by immunohistochemistry with antibodies against BrdU. There was an increase in BrdU labelled cells in the basal layer of the epidermis of H25 transgenic animals on both p53+/+ or 7/7 backgrounds (Figure 6a and b). The labelling is restricted to the basal layer, in keeping with an increase in proliferation rather than unscheduled DNA synthesis associated with DNA repair or altered S phase control. The increase in BrdU labelling is marginally greater in the p53 null animals (Figure 6b ), suggesting that p53 can to some extent restrain proliferation due to MDM2 overexpression. These results show that MDM2 overexpression in the granular layer stimulates DNA synthesis in the basal layer in a largely p53 independent manner. Eects of the suprabasal layer on proliferation of the basal layer has been observed in other studies (Fuchs et al., 1992; Werner et al., 1993) .
MDM2 overexpression induces`apoptosis' detected by the TUNEL assay
There is a ®ne balance in the skin between proliferation in the basal layer and cell death in the granular layer.
We examined if MDM2 expression may aect cell death. DNA strand breaks, a hallmark of cells undergoing apoptosis, were detected by the TUNEL assay. Skin from 4 day old H25 transgenic mice on both p53+/+ and 7/7 backgrounds contained an increased number of labelled cells, mainly in the expanded`granular layer' (Figure 7a ). The increase in apoptotic cells was marginally greater in p53 null animals ( Figure 7b ), which may be a re¯ection of higher proliferation (Figure 6b ). The increase in apoptosis is smaller than the increase in proliferation, in keeping with the increased thickness of the transgenic epidermis.
Altered expression of dierentiation markers in MDM2 transgenic mice
Cells in the skin, as they dierentiate from the basal to the corni®ed layer, express progressively CK14, CK10, CK1, involucrin, loricrin and ®laggrin. The expression of these markers was analysed by immuno-histochemistry of dorsal skin from 4 day old H25 animals on both p53+/+ and 7/7 backgrounds. The results for mice on the same p53 background are directly comparable, since the skin was prepared from littermates and analysed at the same time. Expression of CK14, that is normally restricted to the basal layer, was found, in transgenic mice, to extend over the whole of the expanded epidermis in p53+/+ animals and to be shifted predominantly to the supra-basal layers in p537/7 mice ( Figure 8a ). CK10 and CK1 expression, normally located in the supra-basal layer, was found to extend into higher layers in the transgenics, especially in p537/7 mice ( Figure 8b and not shown). Involucrin and loricrin are expressed in supra-basal layers in both wild type and transgenic animals, but are found in more layers in the transgenics (data not shown). Filaggrin expression is not altered in the transgenics (data not shown). The intensity of staining appeared to be greater in transgenic skin for CK14, CK10, CK1 and involucrin, perhaps because there were more expressing cells (Figure 8 and not illustrated). These results show that MDM2 alters the expression of dierentiation markers, shifting CK14, CK10 and CK1 to upper layers, particularly in p537/7 animals.
Spontaneous tumour development
MDM2 overexpression in the skin and to a lesser extent in other tissues may have increased the number of tumours that developed spontaneously MDM2 induces a skin phenotype M Alkhalaf et al (Table 2 ). We studied visible tumour formation in a group of around 30 animals over an 18 month period. In H25 animals on a wild type p53 background about 20% of the animals developed tumours, which was not signi®cantly higher than the 16% that developed in a comparable group of wild type animals, and was less than the 51% found with p53 null animals. The tumour frequency in transgenic p53 null animals was 40%, which is similar or less than the non-transgenic p53 null group, considering a b c MDM2 induces a skin phenotype M Alkhalaf et al the number of animals studied. These results show that the HCMV-MDM2 transgenic animals do not have a higher susceptibility to spontaneous tumour formation than normal mice.
DMBA and TPA induced carcinogenesis
We studied whether the transgenic animals have an altered susceptible to skin tumorigenesis induced with DMBA and TPA (Brown and Balmain, 1995) . DMBA initiation predominantly results in H-ras mutation. TPA promotion leads to hyperproliferation with the formation of benign papillomas. Malignant conversion to carcinomas is a relatively rare event and depends upon the cell type in which tumour initiation occurs (Brown et al., 1998) . Malignant conversion is enhanced by reduction of p53 gene dosage (Kemp et al., 1993) , raising the possibility that p53 inactivation by MDM2 might have had a similar eect. Wild type and H21 transgenic females were treated with DMBA followed by TPA for 30 weeks, the number of papillomas were counted and plotted as the number per animal with time ( Figure 9 ). Papilloma formation was similar in both groups, ®rst appearing after about 10 weeks, increasing over the next 5 weeks, and then slowly decreasing during the next 15 weeks. There was no obvious morphological dierence between the papillomas in wild type and transgenic animals. In contrast, Kemp et al. (1993) found that carcinomas developed in about 80% of p53 null animals within 15 weeks and about 70% of hemizygous animals within 30 weeks. These results show that the transgenic mice do not have an increased susceptibility to DMBA and TPA induced skin carcinogenesis.
Discussion
A skin phenotype in MDM2 transgenic mice HCMV-MDM2 transgenic mice express MDM2 in the epidermis during the ®rst week after birth. The levels are higher than in other tissues, as shown by Western blotting and immuno-histochemistry of whole body sections (Results and data not shown). There is lower level expression of MDM2 in other mouse tissues in which the CMV promoter is active (Koedood et al., 1995; Schmidt et al., 1990; Kothary et al., 1991; Furth et al., 1991) . High level expression in the skin has not been reported previously (Koedood et al., 1995; Schmidt et al., 1990; Kothary et al., 1991; Furth et al., 1991) , perhaps because of its transient and early nature. The transgenic mice develop a speci®c phenotype, apparently due to the relatively higher level of expression of MDM2 in the skin. We did not detect any other defects, by either macroscopic or microscopic d Figure 4 Histopathology and electron microscopy of the epidermis from wild type and H25 transgenics. (a) Histopathology of the epidermis. Skin from 4 day old animals was ®xed in glutaraldehyde, post-®xed with osmium tetroxide and embedded in Epon 812. Semi-thin sections (1.5 mm) were stained with toluidine blue and observed by light microscopy. WT=wild type; TG=H25 transgenic line; cl=corni®ed layer; tl=transition layer; gl=granular layer; sl=spinous layer; bl=basal layer; de=dermis. The keratohyalin granules are indicated with arrows. Magni®cation: 8006. (b,c). Electron microscopy of the epidermis of wild type (WT) and H25 transgenic (TG) mice. For transmission microscopy (b) ultra-thin sections (70 nm) of skin, ®xed and embedded as above, were contrasted with uranyl acetate and lead citrate and examined with a Philips 208 electron microscope. CL=corni®ed layer; m=mitochondria; d=desmosomes. Arrows point to P-F granules. Arrowheads indicate L-granules. Note the decrease in size and number of the keratohyalin granules in the transgenics. For scanning electron microscopy (c), skin samples were ®xed, stained as above, dried, mounted and observed with a Philips XL-20 microscope. Arrows point to hairs, arrowheads to the scales on top of the corni®ed layer. note that in the transgenic skin the surface is smooth, has lost the corni®ed layer and has less hair. (d) As in (a), except that the H25 mice are on a p53 null background, and the magni®cation is 4006. WT=non-transgenic; TG=H25 transgenic line. The arrowheads in the corni®ed layers point out incompletely corni®ed cellular material that is only seen in the transgenic skin; tl=transition layer; gl=granular layer; sl=spinous layer; bl=basal layer; de=dermis. The keratohyalin granules are indicated with arrows. The dermis below the basal layer is shown only in the WT non-transgenic skin MDM2 induces a skin phenotype M Alkhalaf et al analysis of dierent tissues and whole body sections. It appears unlikely that low level expression of MDM2 in other tissues may have an indirect eect on the skin. The phenotype is observed in the tissue expressing the highest level of MDM2. The severity of the phenotype directly re¯ects MDM2 levels in the skin at dierent ages, between lines and between individuals of the same line.
MDM2 and tumorigenesis
MDM2 over-expression was expected to induce tumour formation. In the CMV-MDM2 transgenic mice there was no increase in either the frequency of spontaneous tumour formation on p53+/+ and 7/7 backgrounds or skin carcinogenesis induced with DMBA and TPA. MDM2 may not be expressed in the right cell types, in a b Figure 5 Immunohistochemical detection of MDM2 expression in the skin of wild type (WT) and H25 transgenic (TG) mice on both p53+/+ (a) and 7/7 (b) backgrounds. Skin was ®xed with 4% paraformaldehyde and embedded in paran. Six mm thick sections were revealed with PAb 365 rabbit polyclonal antibodies to MDM2, incubated with biotin-conjugated anti-rabbit IgG, streptavadin peroxidase conjugate, hydrogen peroxide with DAB chromagen, counterstained with hematoxylin (Histomouse SP kit, Zymed Laboratory) and observed by light microscopy. Controls were treated with biotin-conjugated anti-rabbit IgG alone (not shown). Note the brown nuclear staining of MDM2 that is predominant in the granular layer of the epidermis of the transgenic (TG) skin the right form, at the right time or at sucient levels to induce tumours. MDM2 is expressed in the granular layer of the epidermis, in cells that are in the ®nal stages of dierentiation before cell death and cornification. Skin tumorigenesis is sensitive to the cell type targeted, malignant conversion being primarily observed in hair follicle cells (Brown et al., 1998) . The expressed isoform might not be as transforming as a b Figure 8 Dierentiation of the epidermis analysed with speci®c markers. Six mm thick paran sections of skin from 4 day old wild type (WT) and H25 transgenic (TG) mice on both p53+/+ and 7/7 backgrounds were ®xed with formaldehyde, incubated with rabbit polyclonal antibodies to cytokeratins (CK) 14 and 10 (a, b), incubated with biotin-conjugated anti-rabbit IgG, streptavidin peroxidase conjugate, hydrogen peroxide with AEC chromagen (a, b), counterstained with hematoxylin (Histomouse SP kit, Zymed Laboratory) and observed by light microscopy (magni®cation: 6200). Controls contained biotin-conjugated anti-rabbit IgG alone (not shown)
other variant or mutant forms of MDM2. The transforming properties of MDM2 were established in transfections with the mdm2 gene (Fakharzadeh et al., 1991; Finlay, 1993) , which produces RNAs with dierent coding potential (Barak et al., 1994; Haines et al., 1994; Maxwell, 1994; Olson et al., 1993; BuesoRamos et al., 1995 BuesoRamos et al., , 1996 . Spliced RNAs are expressed at higher levels in tumours and cell lines compared to normal tissues (Sigalas et al., 1996; Montes de Oca Luna et al., 1996) . Some tumours contain MDM2 with mutations in the zinc ®nger (Schlott et al., 1997) . Lundgren et al. (1997) found that MDM2 overexpression in the breast resulted in breast tumours in ®ve out of 16 mice between 14 and 18 months of age. The mammary glands contain many enlarged cells with giant or multiple nuclei (Lundgren et al., 1997) , whereas we could not detect such cells in the skin, suggesting that there is more genetic instability in the breast. Furthermore, elimination of aberrant cells by involution in the breast may be less ecient than corni®cation and desquamation in the skin. The relatively low level of MDM2 expression achieved in the CMV-MDM2 transgenic mice might be the critical reason for the lack of tumour formation. The absolute level of MDM2 required for tumorigenesis in any particular tissue is not known. We are addressing this problem using strong tissue speci®c promoters to drive expression in a more de®ned manner. We are focusing our current experiments on the epidermis, guided by the results with the CMV-MDM2 mice, the availability of strong promoters with de®ned speci®city for particular epidermal cell types and the extensive knowledge of skin developmental and tumour biology. We recently found that three transgenic mice with MDM2 expression targeted to the suprabasal layer with the involucrin promoter (Carroll et al., 1993 (Carroll et al., , 1995 (Carroll et al., , 1997 Crish et al., 1993) have a skin phenotype similar to the CMV-MDM2 mice, and in one of them it was particularly severe (unpublished data). These results show that MDM2 expression directed to the suprabasal layer by two dierent promoters produces a similar phenotype, arguing against the possibility that in the CMV-MDM2 mice the skin phenotype results from an indirect eect of MDM2 expression in a dierent tissue.
The eects of MDM2 are p53 independent
The phenotypes appear to be p53-independent. However, all the phenotypes may not be due to p53 independent functions of MDM2. For example, the distribution of CK1 positive cells in transgenics in the absence of p53 appears to be more restricted. MDM2 regulates factors implicated in keratinocyte differentiation, including E2F1/DP1, pRb and p107 Pierce et al., 1998a) , raising the possibility that they contribute to the skin phenotype.
MDM2 and dierentiation of the skin
Skin dierentiation is inhibited in CMV-MDM2 mice. There is an increase in basal cell proliferation, a shift in CK14, CK10 and CK1 expression to upper layers, and a decrease in the size and number of keratohyalin granules. Granular layer cells have no other abnormalities by electron microscopy, suggesting that the changes are speci®c. MDM2 overexpression in the skin increases the number of apoptotic cells, perhaps as an indirect consequence of faulty dierentiation. MDM2 usually inhibits apoptosis (Kondo et al., 1995; Chen et al., 1996; Haupt et al., 1996) , and skin pathologies are usually associated with increased apoptosis (Raskin, 1997) . The increase in apoptosis is not sucient to compensate for increased proliferation, since the skin is thicker.
MDM2 may have a physiological role in skin dierentiation. MDM2 is transcribed in a p53 independent manner in the basal layer of human skin, and the 90 000 mol. wt. protein is expressed throughout the epidermis (Dazard et al., 1997) . MDM2 is expressed during dierentiation of epidermal keratinocytes in vitro (Weinberg et al., 1995) . MDM2 overexpression may inhibit epidermal dierentiation by preventing exit from the cell cycle, similar to its eects on muscle cell dierentiation (Fiddler et al., 1996) .
The skin phenotype has some similarity to ichthyosis vulgaris, a human genetic disorder of unknown origin, in the: scaly`®sh-skin' appearance, abnormal desquamation, hyperproliferation, decrease in keratohyalin granules, hyperkeratosis and the presence of incomple- H25 transgenic animals on both wild type and p53 null backgrounds were observed for tumour formation from 6 ± 18 months of age in comparison with similar numbers of non-transgenic animals. The number of mice that developed externally visible tumours and the total number of animals are given in brackets. tely dierentiated corneocytes in the corni®ed layer (reviews: Eckert et al., 1997; Epstein, 1996; Francis, 1994; Bale and Doyle, 1994; Williams, 1992) . MDM2 overexpression may mimic ichthyosis vulgaris by inhibiting the synthesis of components of differentiation required for corni®cation. Our study raises the possibility of an important role of MDM2 regulatory circuits in skin dierentiation.
Comparison with the skin phenotype induced by other oncogenes
Transgene expression targeted to the skin has been used to study the properties of a number of oncogene and tumour suppressor gene products (reviews: Brown and Balmain, 1995; Arbeit, 1996) . In common with MDM2, many oncogenes have been shown to stimulate epidermal proliferation (e.g. ras, fos, TGFa, KGF, e bB-2 and IGF-1, see reviews and also Bol et al., 1997 Bol et al., , 1998 Xie et al., 1998) , presumably re¯ecting their eects on dierent pathways that converge on cell cycle control. However, MDM2 overexpression has additional speci®c eects. It is particularly informative to compare the eects of MDM2 and the oncogenes and tumour suppressors that are most directly linked functionally. The E6 and E7 oncogenes of the high risk human papillomaviruses inhibit both p53 and pRb (zur Hausen, 1996) , similar to MDM2. Expression in the basal or suprabasal layers of high risk HPV E6 and E7, either together or separately, leads to hyperproliferation, altered dierentiation and increased apoptosis (Greenhalgh et al., 1994; Auewarakul et al., 1994; Arbeit et al., 1994; Herber et al., 1996; Song et al., 1998) , similar to MDM2. However, unlike MDM2, the E6+E7 mice develop papillomas, that can progress to malignancy depending on the genetic background (Coussens et al., 1996) . The dierence may result from the additional functions of E6+E7 that are not shared by MDM2. p53 inactivation in the basal and suprabasal layers of the epidermis by over-expression of a transdominant negative mutant (p53
172H
, Wang et al., 1998) does not result in an epidermal phenotype but increases susceptibility to DMBA+TPA induced carcinogenesis. p537/7 animals have similar characteristics (Kemp et al., 1993) . MDM2 overexpression produces an epidermal phenotype but not increased susceptibility. The dierences may be a consequence of the p53 independent functions of MDM2, such as those seen in the CMV-MDM2 mice on the p537/7 background.
The pRb pathway has been disrupted by overexpression of cyclin D1 (Robles et al., 1996) , E2F1 (Pierce et al., 1998a,b) and an E1A mutant that inhibits pRB but not p300 (Robles et al., 1996) . MDM2 modulates this pathway directly at the levels of E2F1 and pRb. Inhibition of pRb by overexpression of the E1A mutant has little eect on epidermal proliferation, whereas MDM2 stimulates proliferation. The similarities between MDM2, E2F1 (Pierce et al., 1998a) and cyclin D1 (Robles et al., 1996) are their ability to stimulate proliferation. However, there are notable dierences. E2F1 overexpression increases susceptibility to tumour formation by chemical carcinogenesis (Pierce et al., 1998a) and when combined with the loss of p53 (Pierce et al., 1998b) . Although both E2F1 and MDM2 stimulate apoptosis, the result is expected for E2F1 from studies in cell-lines, whereas it is unexpected for MDM2. E2F1 and cyclin D1 aect proliferation rather dierentiation, since there are increases in the proliferative compartment with only a mild morphological eect in the dierentiated layers and CK1 expression, which is normally restricted to terminally dierentiating cells, is not aected (Pierce et al., 1998a; Robles et al., 1996) . In contrast, MDM2 shifts expression of the dierentiation markers CK1 and CK10 to upper layers, showing that there is an eect on dierentiation as well as proliferation. Finally, the desquamation which is observed with MDM2 has not been described for any of the other oncogenes with overlapping properties. These comparisons suggest the MDM2 phenotype cannot be simply ascribed to increased proliferation. The eects of MDM2 overexpression in the skin do not necessarily indicate that MDM2 normally has a critical function in the aected cell. However, they suggest the possibility of a function of MDM2 in the dierentiation of the epidermis.
Materials and methods
Construction of the HCMV-MDM2 expression vector
The MDM2 construct contains a mouse cDNA clone obtained from a mouse testis library (Stratagene, generously provided by C Theillet, CNRS-Montpellier). This cDNA has three amino acid changes compared to the initially published MDM2 sequence (Fakharzadeh et al., 1991; Dubs-Poterszman et al., 1995; Montes de Oca Luna et al., 1996; 203 T to S, 419 H to D and 486 S to T) . The 5' end of the cDNA was modi®ed to improve the translation eciency by introducing the rabbit b-globin leader sequence. This results in the substitution of a glycine for a cysteine at the second position. A PCR fragment (1470 bp), generated with sense primer: 5'-GCCATGGG-CAATACCAACATGTC-3' and antisense primer: 5'-GACTAGTGGTCAGCTAGTTGAAG-3' (7 min at 908C then 25 cycles, 1 min at 938C, 2 min at 558C and 3 min at 728C), was digested with NcoI and SpeI and cloned downstream from the 60 nucleotides 5' leader of the bglobin cDNA (pT7SAP1B, generously provided by R Treisman). The resulting plasmid was digested with HindIII and SpeI and cloned in the pBKCMV vector (Stratagene) which was digested ®rst with XhoI and blunt ended and then digested with HindIII. The HindIII ± KpnI fragment containing the modi®ed MDM2 was cloned in PXJ41 (Xiao et al., 1991) to generate pCMV/MDM2.
Production of transgenic mice
The CMV/MDM2 transcription unit was prepared by digesting pCMV/MDM2 with PvuI and SalI and purifying the 3 kb fragment (Figure 1a ) with a Gene Clean spin kit followed by an Elutip column and resuspended in 10 mM Tris-HCl pH 7.5, 0.25 mM EDTA. The DNA (2 mg/ml) was microinjected into the pronuclei of fertilised oocytes from F1 super-ovulated (SLJ/C57BL6) females. Eggs that survived microinjection were implanted into the oviduct of pseudopregnant (CD1) foster females. Transgenic mice were identi®ed by PCR and Southern blot using tail DNA. The primers for PCR were: NX30 (b-globin exon 1 sequence) 5'-TGGATCGATCCTGAGAACTT-3'; SC205 (mdm2, exon 4) 5'-AAGCAATGGTTTTGGTCTAAC-3'; SC209 (mdm2, exon 4) 5'-GCTCCTTCACAGAAACTCGG-3' QW236 (mdm2, exon 11) 5'-ACTCTTTTGAAGGAGATCCT-3'; QW238 (mdm2, exon 11) 5'-GCTTGGATGTGCCT-GATGG-3' TY70 (mdm2, exon 12) 5'-CCATCAGGCA-CATCCAAGCC-3'.
Primers QW236 and TY70 amplify two bands (220 bp from the transgenic cDNA sequences, 582 bp from the endogenous mdm2 genomic sequences), NX30 and SC205 one band only (approximately 800 bp from the transgene). Five founders carried the transgene (H21, H25, H5, H20 and H19). The founders and progeny were bred by backcrossing to C57/BL6 mice. All experiments were performed with mice hemizygous for the transgene.
p53 knock-out mice p53-null mice were obtained from the Jackson laboratory (Jacks et al., 1994) . The genotype of the progeny obtained by crossing the p53-null and MDM2 transgenic mice was determined by PCR. To distinguish between the wild type and knock-out copies of p53, a mixture of three primers was used, two sense primers (exon 6 of p53, 5'-ACAGCGTGGTGGTACCTTAT-3' and the neomycin gene, 5'-TCCTCGTGCTTTACGGTATC-3') and one antisense primer (exon 7 of p53, 5'-TATACTCA-GAGCCGGCCT-3').
Histological and ultrastructural analysis
Skin samples were ®xed by immersion in 2.5% glutaraldehyde in 0.1 M cacodylate buer pH 7.2 overnight at room temperature, washed in cacodylate buer for 30 min and post-®xed with 1% osmium tetroxide in 0.1 M cacodylate buer for 1 h at 48C. Tissues were dehydrated with graded concentrations of alcohol (50, 70, 90 and 100%) for 30 min each and embedded in Epon 812. 1.5 mm semi-thin sections were stained with toluidine blue and analysed by light microscopy. 70 nm ultra-thin sections were contrasted with uranyl acetate and lead citrate and then examined with a Philips 208 electron microscope. For scanning electron microscopy, skin samples were ®xed, dehydrated as above, dried with a critical point drying apparatus and then mounted in aluminium stubs coated with palladium-gold using a cold sputter-coater and observed with a Philips XL-20 microscope.
MDM2 and skin marker proteins immunodetection
For indirect immunostaining of MDM2, skin samples were ®xed with 4% paraformaldehyde and embedded in paran. Six mm thick tissue sections were sequentially deparaffinized, incubated with the primary antibody (rabbit polyclonal antibodies to MDM2 (PAb 365, PAb 370; Leveillard and Wasylyk, 1997) , loricrin, involucrin (Medatom Europa), cytokeratins 1, 10, 14 or ®laggrin (generously provided by S Yuspa)), incubated with the secondary antibody (biotin-conjugated anti-rabbit IgG (Jackson laboratory) diluted 1/200 with PBS containing 1% dry milk for 30 min at room temperature), revealed with the Histomouse SP kit (Zymed Laboratory) and analysed by light microscopy. Controls contained biotinconjugated anti-rabbit IgG alone.
For Western immunoblots, skin samples were homogenised with RIPA buer using a UltraThorax homogeniser. Equal amounts of protein were loaded on 10% SDS ± PAGE and transferred to nitro-cellulose membranes. The blots were incubated with MDM2 antibody for 1 h, then incubated with peroxidase-conjugated anti-rabbit IgG (Jackson laboratory) as 1/2000 dilution.
TUNEL assay
Skin from 4 day old wild type and H25 animals on both p53+/+ and p537/7 backgrounds was ®xed in 4% paraformaldehyde and embedded in paran. Six mm sections at room temperature were incubated with proteinase K (20 mg/ml) for 15 min, 2% hydrogen peroxide for 5 min (to quench endogenous peroxidases), rinsed with PBS twice for 5 min, incubated with equilibration buer for 15 min, then at 378C with TDT enzyme in reaction buer for 1 h, followed by room temperature incubations with STOP/WASH buer for 10 min and antidigoxigenin peroxidase for 30 min. Peroxidase activity was detected by incubation in DAB solution for 5 min and tissue sections were stained with 1% methyl green.
BrdU labelling and detection
To label cells in S phase, 4 day old mice were injected subcutaneously with BrdU (50 mg per gram body weight) and sacri®ced 2 h later. Skin samples were ®xed with 4% formaldehyde in PBS and paran embedded. Six mm sections were treated with a biotinylated-monoclonal antiBrdU antibody and revealed according to the manufacturer's instructions (Zymed, # 93-3943).
Chemical carcinogenesis
The long term chemical carcinogenesis protocol (Cui et al., 1996; Santos et al., 1997) was applied to six H21 and 5 wild type control mice at 6 ± 8 weeks of age. The dorsal skin was shaved and 2 days later a single dose of DMBA (25 mg in 200 ml acetone) was applied topically, followed by TPA (200 ml of a 10 74 M solution in acetone) twice weekly for 20 weeks. The number of papillomas was recorded every week for 44 weeks post DMBA.
